Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | ELANE | P08246 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3576904 | 0.85 | GAA (0.56) | GAAPOLBSMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL25094432 | 0.85 | GAA (0.56) | GAAPOLBSMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL19961833 | 0.85 | GAA (0.56) | GAAPOLBSMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL2296725 | 0.82 | POLB (0.58) | GAAPOLBSMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL2296722 | 0.82 | POLB (0.58) | GAAPOLBSMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL31208299 | 0.82 | POLB (0.58) | GAAPOLBSMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL30201901 | 0.81 | POLB (0.54) | GAAPOLBSMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL21501547 | 0.81 | GAA (0.51) | GAAPOLBSMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL527771 | 0.79 | GAA (0.58) | GAAPOLBSMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL22116031 | 0.79 | GAA (0.50) | GAAPOLBSMN1; SMN2ALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240016152-A1 | ACTIVE COMPOUND COMBINATIONS | BAYER AKTIENGESELLSCHAFT (DE) | 2024-01-18 | — | — | US | disclosed |
| US-20230295138-A1 | HETEROCYCLYL PYRIDINES AS NOVEL FUNGICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 2023-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240016152-A1 | ACTIVE COMPOUND COMBINATIONS | CYP51A1, ERG28, BROX | GAA 231/4885POLB 2728/4885SMN1; SMN2 4195/4885 |
| US-20230295138-A1 | HETEROCYCLYL PYRIDINES AS NOVEL FUNGICIDES | PNPO, CBR3, HPD | GAA 812/4885POLB 4234/4885SMN1; SMN2 4583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.